William D. Tap

Active 1995–2025

163
Papers
23,412
Citations
75
h-index
152
i10-index

Citations

Citations per year for William D. Tap1976: 1 citations1977: 1 citations1995: 1 citations1996: 11 citations1997: 6 citations1998: 4 citations1999: 2 citations2000: 2 citations2001: 5 citations2002: 2 citations2004: 3 citations2006: 2 citations2007: 1 citations2008: 3 citations2009: 11 citations2010: 14 citations2011: 15 citations2012: 32 citations2013: 41 citations2014: 47 citations2015: 68 citations2016: 98 citations2017: 170 citations2018: 144 citations2019: 758 citations2020: 1,229 citations2021: 1,327 citations2022: 1,163 citations2023: 904 citations2024: 1,479 citations2025: 690 citations2026: 14 citations1978–1994: no citations, so these years are not shown2003: no citations, so this year is not shown2005: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,944 citing papers, 27.2% of this breakdownChina: 1,665 citing papers, 15.4% of this breakdownUnited Kingdom: 593 citing papers, 5.5% of this breakdownItaly: 558 citing papers, 5.1% of this breakdownGermany: 519 citing papers, 4.8% of this breakdownFrance: 475 citing papers, 4.4% of this breakdownCanada: 374 citing papers, 3.4% of this breakdownNetherlands: 372 citing papers, 3.4% of this breakdownSpain: 335 citing papers, 3.1% of this breakdownJapan: 302 citing papers, 2.8% of this breakdownAustralia: 249 citing papers, 2.3% of this breakdownSwitzerland: 220 citing papers, 2% of this breakdown
0%27.2%Other 20.6%

Fields

  • Medicine70.3%
  • Biochemistry, Genetics and Molecular Biology19.4%
  • Immunology and Microbiology6.3%
  • Neuroscience1%
  • Engineering0.6%
  • Computer Science0.5%
  • Other1.9%

Topics

  • Cancer Immunotherapy and Biomarkers7.9%
  • Sarcoma Diagnosis and Treatment7.5%
  • Cancer Genomics and Diagnostics3.6%
  • CAR-T cell therapy research3.4%
  • Immunotherapy and Immune Responses3.1%
  • Ferroptosis and cancer prognosis2.3%
  • Other72.2%

Coauthors

All papers

Open in search
  1. Tumor mutational load predicts survival after immunotherapy across multiple cancer types

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philip H. Gutin, Cameron Brennan, Viviane Tabar, Ingo K. Mellinghoff, Lisa M. DeAngelis, Charlotte E. Ariyan, Nancy Y. Lee, William D. Tap, Mrinal M. Gounder, Sandra P. D’Angelo, Leonard B. Saltz, Zsofia K. Stadler, Howard I. Scher, José Baselga, Pedram Razavi, Christopher A. Klebanoff, Rona Yaeger, Neil H. Segal, Geoffrey Y. Ku, Ronald P. DeMatteo, Marc Ladanyi, Naiyer A. Rizvi, Michael F. Berger, Nadeem Riaz, David B. Solit, Timothy A. Chan, Luc G.T. Morris - Nature Genetics 2019 cited by 4,358

  2. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yelena Y. Janjigian, Michael J. Morris, Robert J. Motzer, Eileen M. O’Reilly, Michael A. Postow, Nitya Raj, Gregory J. Riely, Mark E. Robson, Jonathan E. Rosenberg, Anton Safonov, Alexander N. Shoushtari, William D. Tap, Min Yuen Teo, Anna M. Varghese, Martin H. Voss, Rona Yaeger, Marjorie G. Zauderer, Nadeem R. Abu‐Rustum, Julio García‐Aguilar, Bernard H. Bochner, A. Ari Hakimi, William R. Jarnagin, David R. Jones, Daniela Molena, Luc G.T. Morris, Eric Rios‐Doria, Paul Russo, Samuel Singer, Vivian E. Strong, Debyani Chakravarty, Lora H. Ellenson, Anuradha Gopalan, Jorge S. Reis‐Filho, Britta Weigelt, Marc Ladanyi, Mithat Gönen, Sohrab P. Shah, Joan Massagué, Jianjiong Gao, Ahmet Zehir, Michael F. Berger, David B. Solit, Samuel F. Bakhoum, Francisco Sánchez-Vega, Nikolaus Schultz - Cell 2022 cited by 663

  3. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tianjiao Wang, Jane P. F. Bai, Stavros Rafail, Ruoxi Wang, Amy Sun, Lilliam Fernandes, Erin Van Winkle, Erica Elefant, Colin Lunt, Elliot Norry, Dennis Williams, Swethajit Biswas, Brian Andrew Van Tine - The Lancet 2024 cited by 263

  4. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

    Authors: , , , , , , , , , , - The Lancet Oncology 2018 cited by 748

  5. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2019 cited by 474

  6. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , C. M. Gee, Brian L. West, Peter Hirth, K. B. Nolop, Matt van de Rijn, Henry H. Hsu, Charles Peterfy, Paul Lin, Sandra Tong-Starksen, Gideon Bollag - New England Journal of Medicine 2015 cited by 582

  7. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Neerav Shukla, Martee L. Hensley, John H. Healey, Michael P. LaQuaglia, Kaled M. Alektiar, Aimeé M. Crago, Sam S. Yoon, Brian R. Untch, Sarah Chiang, Narasimhan P. Agaram, Meera Hameed, Michael F. Berger, David B. Solit, Nikolaus Schultz, Marc Ladanyi, Samuel Singer, William D. Tap - Nature Communications 2022 cited by 211

  8. CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

    Authors: , , , , - Cancer Cell 2018 cited by 393

  9. Cancer Disparities and Health Equity: A Policy Statement From the American Society of Clinical Oncology

    Authors: , , , , , , - Journal of Clinical Oncology 2020 cited by 329

  10. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2018 cited by 435

  11. Sorafenib for Advanced and Refractory Desmoid Tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 449

  12. Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Garrett M. Frampton, Jeffrey M. Venstrom, Jeffrey S. Ross, Marc Ladanyi, Samuel Singer, Murray F. Brennan, Gary K. Schwartz, Alexander J. Lazar, David M. Thomas, Robert G. Maki, William D. Tap, Siraj M. Ali, Dexter X. Jin - Nature Communications 2022 cited by 193

  13. The epigenomics of sarcoma

    Authors: , , , , , , , - Nature reviews. Cancer 2020 cited by 208

  14. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Genetics 2014 cited by 633

  15. Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Roberta Maestro, Rafael Marcos‐Gragera, Javier Martín‐Broto, Tomohiro Matsuda, Olivier Mir, Shreyaskumar Patel, Chandrajit P. Raut, Albiruni R. Abdul Razak, Damon R. Reed, Piotr Rutkowski, Roberta Sanfilippo, Marta Sbaraglia, Inga‐Marie Schaefer, D. Strauß, Kirsten Sundby Hall, William D. Tap, David M. Thomas, Winette T.A. van der Graaf, Winan J. van Houdt, Otto Visser, Margaret von Mehren, Andrew J. Wagner, Breelyn A. Wilky, Young‐Joo Won, Christopher D.�M. Fletcher, Angelo Paolo Dei Tos, Annalisa Trama - Cancer 2021 cited by 227

  16. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael J. Morris, Robert J. Motzer, Eileen M. O’Reilly, Michael A. Postow, Nitya Raj, Gregory J. Riely, Mark E. Robson, Jonathan E. Rosenberg, Anton Safonov, Alexander N. Shoushtari, William D. Tap, Min Yuen Teo, Anna M. Varghese, Martin H. Voss, Rona Yaeger, Marjorie G. Zauderer, Nadeem R. Abu‐Rustum, Julio García‐Aguilar, Bernard H. Bochner, A. Ari Hakimi, William R. Jarnagin, David R. Jones, Daniela Molena, Luc G.T. Morris, Eric Rios‐Doria, Paul Russo, Samuel Singer, Vivian E. Strong, Debyani Chakravarty, Lora H. Ellenson, Anuradha Gopalan, Jorge S. Reis‐Filho, Britta Weigelt, Marc Ladanyi, Mithat Gönen, Sohrab P. Shah, Joan Massagué, Jianjiong Gao, Ahmet Zehir, Michael F. Berger, David B. Solit, Samuel F. Bakhoum, Francisco Sánchez-Vega, Nikolaus Schultz - 2021 cited by 69

  17. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2020 cited by 205

  18. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas

    Authors: , , , , , , , , , , , , , , , , , , , , , - JAMA 2020 cited by 301

  19. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 cited by 304

  20. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2017 cited by 306

  21. Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 156

  22. Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO–Friends of Cancer Research Joint Research Statement

    Authors: , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2021 cited by 111

  23. Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 169

  24. A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2023 cited by 69